Νεότερα DES stents. Δεδοµένα εφαρµογής των και προοπτικές
|
|
- Alan Jacobs
- 6 years ago
- Views:
Transcription
1 Νεότερα DES stents. Δεδοµένα εφαρµογής των και προοπτικές Δηµήτρης Γ. Σιώνης Αιµοδυναµικό Τµήµα Επεµβατικής Καρδιολογίας Σισµανόγλειο-Αµ. Φλέµιγκ ΓΝ Αθήνα
2 Δήλωση συµφερόντων None for the presentation Potential conflicts of interest Institutional research grant : Elpen, Sanofi, Boehringer Ing Honoraria : Medtronic, Sanofi
3 1 st -Generation DES was not ideal for healing Thick struts Thick, durable coating (~15 µm) High drug dose High polymer load Uncovered struts Hypersensitivity Malapposition Late stent thrombosis Neoatherosclerosis Th Th Th Th Uncovered struts Hypersensitivity reaction Malapposition from excessive fibrin deposition Neoatherosclerosis Virmani, CRT 2014
4 2 nd gen DES perm polymer: Improved efficacy and safety Data from Spirit II,III,IV and COMPARE trials (6789)
5 Event rates persist beyond 1 year with 2 nd gen PERMANENT Polymer DES TLF Rate (%) RESOLUTE All Comers Resolute ZES (N=1140) Xience V EES (N=1152) Primary endpoint Pnon-inferiority < % 8.2% Log rank P= % 16.3% Years 2% event rate per year Windecker PCR 2014
6 Etiology of metallic stents events Within 1 year Early thrombosis and restenosis Early DAPT discontinuation Suboptimal implantation (under expansion, malapposition, geographic miss, edge dissections) Longitudinal stent deformation Strut fracture Polymer defects or stripping during delivery Inflammation/hypersensitivity from the polymer/drug Non responsiveness to drug Beyond 1 year Very late thrombosis and restenosis Uncovered struts (thrombosis) Abnormal shear stress from protruding struts and/or loss of cyclic strain relief Strut fracture Persistent stimulation of SMC s from adherent fibrin and/or loss of normal vessel curvature Chronic inflammation due to late foreign body reactions and polymer hypersensitivity Positive remodeling with strut malapposition Neoatherosclerosis
7 Approaches to improve Next Generation metallic DES outcome Deliverable, Visible, Trackable Conformable No Stent Thrombosis Short DAPT duration Low TLR, Low Clinical Symptom Recurrence Improved Stent Delivery System Stent Material Thinner Struts Modified Stent Geometry Enhanced side-branch access Surface Coating Facilitating re-endothelialization Polymer facilitating endothelialization Durable, but more biocompatible Reduced Polymer Load Abluminal Polymer No Polymer Bioabsorbable Polymer Reduced Drug Load Less/no effect on endothelial function
8 Approaches to improve early and late DES outcomes Metallic DES with thinner struts
9 Thin Struts Restenosis and Thrombosis 1. ISAR STEREO 1, Circulation ISAR STEREO 2 JACC Kolandaivelu et al Circulation 2011
10
11
12 Approaches to improve early and late DES outcomes Metallic DES polymer-free Metallic DES with bioabsorbable polymers Bioresorbable scaffolds (BRS)
13 HYPOTHESIS: Polymers play a role in phenomena observed with DES ANEURYSMS, HYPERSENSITIVITY, LATE RESTENOSIS, LISA VASO- CONSTRICTION a INCREASED INFLAMMATION b PRO- THROMBOGENIC b DELAYED HEALING c Decreased Endothelial Function Illustration based on Beckmann JA et al. JAMA. 2002;287(19): and Roesen P et al. Exp Clin Endocrinol Diabetes. 2001;109(supp 12):S474-S486. a Tongi et al. Int J Cardiol. 2007;120:212. b Joner et al. J Am Coll Cardiol. 2006;48: c Awata et al. ACC
14 Polymer Free Design Types 1.Bioactive agent in pure form, impregnated in porus surface or stent body Nano/micro can use metal sieve structure to control release kinetics Macro or wells-diffusion depends primarily on pharmacokinetic properties of the agent 2.Bioactive agents dissolved in a non-polymeric biodegradable carrier. On surface of stent In a nano-micro structure Biosensors Translumina Setagon Medronic Ziscoat 3.Bioactive agent attached to stent surface Covalent bonding Chemical precipitation or crystalization on stent surface Amazonia PAX
15 Urban F et al, NEJM 2015 Leaders Free trial Age>75 years OAC planned after PCI Baseline Hb <11g/dl or transfusion prior 4 weeks Planned major surgery Cancer diagnosed or treated <3 years Creatinine clearance <40ml/min Hospital admission for bleeding during past year Thrombocytopenia (< /mm3) Any prior intra-cerebral bleed Any stroke during the past year Severe liver disease NSAID or steroids planned after PCI Anticipated poor DAPT compliance for other medical reason Primary Efficacy Endpoint Clinically Driven TLR Primary Safety Endpoint Cardiac Death, MI, ST
16 The Drug Filled Stent-Concept (Medtronic) Drug (sirolimus) is protected and contained inside the stent Drug releases through multiple laser-drilled holes on the abluminal side of the stent Drug elution is controlled and sustained through natural diffusion via direct interaction with the vessel wall. Elution profile is similar to durable polymer DES Drug coats inner lumen Drug elutes through abluminal holes Uniform distribution in stented area
17 Case by Prof. Stephen Worthley. OCT Analysis by Daniel Chamié, MD, OCT Core Laboratory, Cardiovascular Research Center, Sao Paulo, Brazil DFS case, Early Healing of Overlapping Struts Post-Procedure Age (yrs) 60 Gender (M/ F) Diabetes (Y/N) F Y(ID) RVD (mm) 3.0 Lesion Length (mm) Lesion location 46 Mid RCA 1-Month Followup 0.6 mm 14 mm 17 mm 17.8 mm 42.2 mm
18 Approaches to improve early and late DES outcomes Metallic DES polymer-free Metallic DES with bioabsorbable polymers Bioresorbable scaffolds (BRS)
19 Vascular Response to Durable Polymers Newer generation durable polymers are still a source of inflammation, neoatherosclerosis and thrombosis risk Virmani et al TCT 2012
20 Time Course For Polymer Bioabsorption BioMime (PLLA+PLGA) SYNERGY (PLGA) Ultimaster (PLLA - CL) MiStent (PLGA) ABLUMINUS (PLA) ELIXIR DESyne BD (PLA) FIREHAWK (PLA) BIOMATRIX (PLA) NOBORI (PLA) SVELTE (Amino Acid) ORSIRO (PLLA) REAMS 2 (Mg w/pla coat) ART (PDLLA) ELIXIR DESolve (PLLA) BVS (PLLA) REVA ReZolve (Polycarb) (no drug) Time (Months) Drug Release Bioabsorbable Polymer Bioresorbable Scaffold (BRS)
21
22 An abluminally coated bioabsorbable polymer DES be optimal for healing? may Uncoated surface on luminal side to promote cell coverage and adhesion Freedom from long-term polymer exposure once coating is absorbed Strut Vessel Lumen Arterial Wall Targeted drug delivery reduces risk of restenosis and inflammation
23 SYNERGY OCT Results in All Comers Patients Understanding healing from 30 Days 6 Months 30 days 3 Months 6 Months 72.2% Covered 99.3% Covered* 94.5% Covered 96.6% Covered N=30 N=37 N=22 N=20 SORT-OUT VIII PCR 2015 TIMELESS CRT 2015 De la Torre CCI % Thrombosis De la Torre CCI 2015
24 EVOLVE II TLF at 2 years PROMUS Element Plus vs SYNERGY TLF (%) Endpoint: 12 months ITT P noninferiority = years HR 1.10 [0.79, 1.52] P= % 8 6.7% 8.5% 4 6.5% No. at Months risk PE SYNERGY ITT Population; Patients who did not receive a study stent were censored at 1 year; KM Event Rates; log-rank P values Kereiakes, ACC 2016
25 3 rd generation
26 Approaches to improve early and late DES outcomes Bioresorbable scaffolds (BRS) Absence of metallic cage
27 4 th Evolution in Coronary Angioplasty Bioresorbable Scaffold Lifecycle - Polymer exposure - Drug elution to reduce risk - Drug elution complete complete of restenosis - Mechanical support to maintain - Scaffold support no longer - Mechanical support to patency required maintain patency - Natural vasomotion and positive remodeling REVASCULARIZATION RESTORATION enabled RESORPTION Scaffold Mass Drug Elution Scaffold Support Months Forrester, et al. J Am Coll Cardiol. 1991: Oberhauser, et al. EuroInterv.
28 Available and upcoming Bioresorbable Scaffolds
29 First Generation BVS The Absorb Series Everolimus/PDLLA (1:1) matrix coating 7µm Conformal coating Controlled drug release similar to Xience CoCr-EES -Impressive results of pivotal trials -Non inferior to 2 nd gen DES -First signs of safety issues in GHOST trial (2.1% thrombosis)
30 1 st gen BVS Meta-Analyses Comparison Target Lesion Failure Absorb (%) Xience (%) Odds Ratio (95% CI) P value Cassese et al, % 5.1% 1.20 [0.9, 1.6] 0.21 Stone et al, % 5.1% 1.25 [0.92, 1.70] 0.18 Myocardial Infarction Cassese et al, % 3.5% 1.36 [0.98, 1.89] 0.06 Stone et al, % 4.0% 1.34 [0.97, 1.85] 0.07 Lipinski et al, % 1.5% 2.06 [1.31, 3.22] Stent Thrombosis (def/prob) Cassese et al, % 0.5% 1.99 [1.00, 3.98] 0.05 Stone et al, % 0.6% 2.09 [0.92, 4.75] 0.08 Lipinski et al, % 0.7% 2.06 [1.07, 3.98] Absorb better Xience better Cassese, et al. The Lancet 2016; 387: Lipinski, et al. JACC Cardiovasc Interv 2016;9: Stone, et al. The Lancet 2016 [epub ahead of print].
31
32 Possible Causes of Increased ST Rates with ABSORB Poor Lesion Preparation Thick Struts (157µm overlapping 354µm) Non-laminar Flow Inadequate Post-dilatation Malapposition Delayed Healing Fractures Proposed solutions Use in >2.5mm vessels Need for proper preparation Adequate postdilatation Avoid overlapping scaffolds Thrombosis Strut Fracture Malapposition Underexpansion Thick Struts 1 Jaguszewski, M. Eur Heart J. Feb 2015 [Epub ahead of print]. 2 Ormiston, et al. Circ Cardiovasc Interv. 2011;4: RadcliffeCardiology.com, September Sipotz, J. presented at TCT2014. Capodanno, et al. EuroIntervention 2015 Feb;10(10):
33 DESolve Bioresorbable Coronary Scaffold- elutes for 3 months absorbs in 2 years 3.4m m Hierarchical Events (n,%) 3.8m m Verheye et al, JACC Interv M (N=122) 12M (N=122) 4.0m m 24M (N=122) 4.75m m 36M (N=122) Major Adverse Cardiac Events 3.3% 5.7% 7.4% 8.2% Cardiac Death 1(0.8%) 2 (1.6%) 3 (2.5%) 4 (3.3%) Target Vessel MI Q wave Non Q wave MI 1(0.8%) 0(0,0%) 1(0.8%) 1 (0.8%) 0 (0,0%) 1 (0.8%) 1 (0.8%) 0 (0,0%) 1 (0.8%) 1 (0.8%) 0 (0,0%) 1 (0.8%) Clinically Indicated TLR 2 (1.6%) 4 (3.3%) 5 (4.1%) 5 (4.1%) Definite Stent Thrombosis 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
34 BIOTRONIK Mg BRS Magmaris results
35 Bioresorbable Scaffolds data The Idea. the Data.. the Future Absence of Permanent Rigid Metallic Cage Preservation of targets for CABG Restoration of vasomotion Late luminal enlargement Significantly longer procedure time Significantly lower acute gain and post procedure MLD Numerically high adverse event rates even in relatively simple lesions Signal for high rates of late events More than 8 studies with >2% ST at 1 year in realworld populations Strut thickness Fracture resistance Visibility Absorption time Radial force Clinical data Future (near) BRS
36 Bioresorbable scaffolds Next Gen Absorb 120 NG Absorb 2 Magmaris BOSTON s RENUVIA Bioresorbable Scaffold Bioresorbable Microfiber Scaffold (BRMS)- MIRAGE Medtronic Mg Absorbable Scaffold Puricel et al, JACC 2016;67:
37 Conclusions Current metallic DES (either with durable or bioabsorbable polymer) have shown excellent safety and efficacy, therefore remain the default treatment for CAD either SIHD or ACS. Bioabsorbable polymer DES seem to offer advantages over durable polymer DES but are not a homogenous class Novel technologies include advantages on stent design and platform (DFS, polymer-free) may show further advantages of metallic DES. 1 st generation BRS use face problems short and long term as far as the efficacy and safety of the devices Possible overcome of these limitations can be achieved with the development of 2 nd generation BRS and the refinement of the deployment procedure Till then, the Operator is a major factor in the efficacy and safety of 1 st generation BRS, being an
38
39 Stent Thrombosis at 36 months Definite ST Definite, Probable or Possible ST Orsiro Xience Prime Orsiro Xience Prime (N=298) (N=154) (N=298) (N=154) Acute (0-48h) 0 % 0 % Acute (0-48h) 0 % 0 % Subacute (48h-30d) 0 % 0 % Subacute (48h-30d) 0 % 0 % Late (>30d) 0 % 0 % Late (>30d) 0 % 0 % Very late (>12m) 0 % 0 % Very late (>12m) 0 % 0.7 % Overall 0 % 0 % Overall 0 % 0.7 %* * One possible very late ST occured in a diabetic patient in the Xience Prime arm Source: T. Slagboom, Poster, EuroPCR 2015
40 Bioresorbable Scaffolds data The Idea. the Data.. the Future Absence of Permanent Rigid Metallic Cage Restoration of vasomotion Late luminal enlargement Preservation of targets for CABG Appeal to physician/ patient Freedom from longterm polymer exposure Angina relief Significantly longer procedure time Significantly lower acute gain and post procedure MLD Numerically high adverse event rates even in relatively simple lesions Signal for high rates of late events More than 8 studies with >2% ST at 1 year in realworld populations Strut thickness Fracture resistance Visibility Absorption time Radial force Clinical data Future (near) BRS
Bioresorbable Stents: Innovation or Bust?
Bioresorbable Stents: Innovation or Bust? Rajiv Jauhar, MD FACC, FSCAI Chief of Cardiology Director of Cardiac Cath Labs Northshore University Hospital San Diego July, 2016 Conflict of Interest Disclosure
More informationBioresorbable stents for all or for few? Franz-Josef Neumann
Bioresorbable stents for all or for few? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria, consultancy fees and research grants from Lilly, Daiichi Sankyo, Sanofi-Aventis,
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationCoronary Stents: Past, Present, Future
Coronary Stents: Past, Present, Future Michael C Kim, MD FACC Director Cath Lab and IC Lenox Hill Heart and Vascular Institute Northwell Health IC-296208-AN DEC 2016 Page 1 1st-Generation DES was not ideal
More informationWhat Stent to Use? JASVINDAR SINGH MD, FACC
What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationPCI with Polymer-free Stent
PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationΕνδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ
Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ DES Penetration -(2011) Source: Millenium Research Group Cordis has stopped manufacturing
More informationDevice and Clinical Program Highlights: SINOMED BuMA Stent
Device and Clinical Program Highlights: SINOMED BuMA Stent Runlin Gao, MD, FACC, FESC, FSCAI Fuwai Hospital, National Center for Cardiovascular Diseases, China CAMS, PUMC BuMA Supreme Platform and Pre-Clinical
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More informationBIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions
BIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions Johannes Waltenberger, MD, F.E.S.C. Uniklinik Münster Münster, Germany
More informationProspective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results
Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results Stefan Verheye, MD PHD ZNA Middelheim Antwerp, Belgium Potential
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationDrug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition
Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J
More informationBioresorbable Scaffolds Moving Forward or Backwards?
Bioresorbable Scaffolds Moving Forward or Backwards? George D. Dangas, MD, FACC, MSCAI Professor of Cardiology & Vascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Disclosure Statement
More informationCurrent Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationVascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts
Vascular Intervention // Coronary Drug-Eluting Stent System Clinically proven Highly deliverable Ultrathin 60 μm struts The new benchmark for DES BIOFLOW-V 12-month clinical outcomes compared to Xience
More informationBiodegradable Polymer coated Drug Eluting Stents Versus Durable Polymer coated Drug Eluting Stents for Percutaneous Coronary Intervention
Biodegradable Polymer coated Drug Eluting Stents Versus Durable Polymer coated Drug Eluting Stents for Percutaneous Coronary Intervention Amos Levi, MD, Tamir Bental, MD, Abid R Assali, MD, Hanna Vaknin-Assa,
More informationNEW GENERATION DES WITH NEW GENERATION POLYMERS. Prof. Dr. Rainer Wessely, Duisburg, Germany
NEW GENERATION DES WITH NEW GENERATION POLYMERS Prof. Dr. Rainer Wessely, Duisburg, Germany Sousa J et al., JACC Cardioasv Interv 2010 10 years DES NEXT DES BMS + DAPT DES DES + DAPT S A F E T Y BMS E
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationBIOFLOW by Orsiro stents
BIOFLOW by stents Byeong-Keuk Kim, MD, PhD Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine Key Benefits Clinically proven
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI, FAPSIC MonashHeart, Monash Medical Centre & Monash University Melbourne, Australia
Final five-year clinical outcomes in the EVOLVE trial: A randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian T. Meredith AM MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI,
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationINTERVENTIONAL CARDIOLOGY Bioresorbable Stents Update: Similarities. Generation BVS
INTERVENTIONAL CARDIOLOGY 2017 32 ND ANNUAL INTERNATIONAL SYMPOSIUM Bioresorbable Stents Update: Similarities and Differences in Comparison to First Generation BVS Dariusz Dudek Institute of Cardiology
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationMagmaris: the impact of scaffold design and materials on reducing thrombogenicity
: the impact of scaffold design and materials on reducing thrombogenicity Michael Joner, MD Deutsches Herzzentrum München und Deutsches Zentrum für Herz-Kreislaufforschung e.v. Potential conflicts of interest
More information2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES
2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES Marlies M. Kok, MD Thoraxcentrum Twente, MST, Enschede, the Netherlands On behalf of the BIO-RESORT
More informationEluNIR. Ridaforolimus Eluting Coronary Stent System. Advancing Deliverability for the Road Ahead
Ridaforolimus Eluting Coronary Stent System Advancing Deliverability for the Road Ahead The Coronary Stent System Raising the Bar on Drug-Eluting Stent Technology Introducing the Coronary Stent System,
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationMagmaris Stent (Biotronik) A Pichard, Ron Waksman. Medstar Washington Hospital Center Washington, DC
Magmaris Stent (Biotronik) A Pichard, Ron Waksman. Medstar Washington Hospital Center Washington, DC Conflict of Interest None for this presentation Downside of Metallic Stents 1. Restenosis No longer
More informationResults of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
More informationΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ
ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ Νίκος Μεζίλης MD, FESC Κλινική Άγιος Λουκάς Why diabetes is associated with restenosis endothelial dysfunction metabolic alterations accelerated platelet deposition
More information1/22/2017. Ultimaster Clinical evidence. Hazem Khamis,MD,FACC October 6 University Egypt
Ultimaster Clinical evidence Hazem Khamis,MD,FACC October 6 University Egypt Vienna November 2012 1 2 IC-215303-AA JAN2014 5 of 25 IC-215303-AA JAN2014 6 of 25 1/22/2017 Key Elements of Stent for Complex
More informationBioabsorbable Scaffolds: The Next Holy Grail?
Bioabsorbable Scaffolds: The Next Holy Grail? New Cardiovascular Horizons New Orleans, LA June 06, 2013 Lewis B. Schwartz, M.D., F.A.C.S. Vascular Surgery and Endovascular Therapy University of Chicago
More informationΒιοαποδομήσιμα Στεφανιαία Ικριώματα με βάση το μαγνήσιο. Magnesium Bioresorbable Coronary Scaffolds
Βιοαποδομήσιμα Στεφανιαία Ικριώματα με βάση το μαγνήσιο. Magnesium Bioresorbable Coronary Scaffolds Βάιος Π. Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Ερρίκος Ντυνάν HC Δεν υπάρχει σύγκρουση συμφερόντων
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationDisclosure Eberhard Grube, M.D.
Disclosure Eberhard Grube, M.D. I disclose the following financial relationships: Consultant Sadra Medical, Core Valve, Biosensors, Orbus Neich, Cordis Johnson & Johnson, Boston Scientific, Mitralign,
More informationUltimaster clinical results in left main and bifurcations
Left main and complex bifurcation stenting clinical results in left main and bifurcations GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of Cardiovascular and Pulmonary Sciences
More informationWhat s New in Antiplatelet Therapy and DES in 2016
What s New in Antiplatelet Therapy and DES in 2016 Peter Pollak MD Director of Structural Heart Disease & Intervention Mayo Clinic Florida 2016 slide-1 Disclosures Financial None Off-label - None 2016
More information生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所
生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所 PCI milestones Pre Post Biodegradable polymer? 1 st revolution 1977 PTCA 2 nd revolution 1988 BMS 3 rd revolution 2000 DES Bioresorbable
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationYukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up
Sirolimus Eluting CoCr Coronary Stent System Yukon Chrome PC 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts Yukon Chrome PC DES coating with excellent long-term
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationResults of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
More informationHow to Predict & Prevent It! George D. Dangas, MD, FACC, FESC
Stent Thrombosis How to Predict & Prevent It! George D. Dangas, MD, FACC, FESC Professor of Cardiology & Vascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Καθηγητής Καρδιολογίας ΕΚΠΑ
More informationBioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
Bioabsorbable Scaffolding: Technology and Clinical Update PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland Disclosures I am not Ron Waksman 1 Clinical experience with AMS
More informationPercutaneous Coronary Intervention: an Update for the Internist
Percutaneous Coronary Intervention: an Update for the Internist Michael W. Cammarata, MD, MS Boca Raton Reginal Hospital Grand Rounds January, 9 2018 Objectives/Outline Background/Introduction Patient
More informationDual-therapy stent technology for patients with coronary artery disease Kalkman, D.N.
UvA-DARE (Digital Academic Repository) Dual-therapy stent technology for patients with coronary artery disease Kalkman, D.N. Link to publication Citation for published version (APA): Kalkman, D. N. (2018).
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA152 drug-eluting stents for the treatment of coronary artery disease (part review of TA71) this guidance was originally
More informationSafety of Drug-Eluting Stents in Acute Coronary Syndromes
Rotterdam, June 11 th 2012 Safety of Drug-Eluting Stents in Acute Coronary Syndromes Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationThe role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium
The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium Disclosures Speaker name: Frank Vermassen I have the following potential
More informationReZolve2 Bioresorbable Coronary Scaffold Clinical Program Update
ReZolve2 Bioresorbable Coronary Scaffold Clinical Program Update Dr. David Muller St Vincent s Hospital Sydney, Australia 0 Potential conflicts of interest Speaker's name: Dr. David Muller I do not have
More informationYukon Choice PC Translumina trust is what counts
Sirolimus Eluting Coronary Stent System 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts DES with excellent long-term clinical outcome The Translumina PC drug-eluting
More informationWhat Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas
What Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas Stent Era Lessons on Vessel Preparation Under expanded stent consequences Abrupt
More informationReduction in Stent Thrombosis better tablets or better stents?
Reduction in Stent Thrombosis better tablets or better stents? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton MY CONFLICTS OF INTEREST ARE Speaker Fees/Honoraria/Travel Support Lilly/Daiichi
More informationAbsorbable Scaffolds the Future of Coronary Interventions?
Absorbable Scaffolds the Future of Coronary Interventions? Brock Cookman, DO, MSA Interventional Cardiology Mercy Heart and Vascular Institute April 8, 2017 None Disclosures Objectives History of cardiac
More informationInspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil
Stent Clinical Research Program Pedro A. Lemos MD PhD Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil All faculty disclosures are available on the CRF Events App and online
More informationOptimal Revascularization in Multivessel Disease and Coronary CTO. Dr Simon Walsh MD FRCP FSCAI Consultant Cardiologist Belfast Trust
Optimal Revascularization in Multivessel Disease and Coronary CTO Dr Simon Walsh MD FRCP FSCAI Consultant Cardiologist Belfast Trust Potential Conflicts of Interest Speaker's name: Simon Walsh Consulting
More informationAlien vs Terminator? 11/30/2016. Absorb vs Synergy Clinical Efficacy -Review of Absorb 3 and Evolve 2 Trials
Absorb vs Synergy Clinical Efficacy -Review of Absorb 3 and Evolve 2 Trials Dr. Marc Litt Director Cardiac Cath Lab Baptist Medical Center Jacksonville,Flordia ABSORB BVS GT 1 VS SYNERGY Bioresorable PLLA
More informationFreedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK
Freedom to Treat Your High Bleeding Risk Patients Tim Kinnaird University Hospital of Wales, Cardiff, UK Relevant Disclosures Honoraria for lectures from: o Eli Lilly & Co, Daiichi Sankyo, Boehringer,
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationMedical Product Development: Commercial Success Extends Beyond Regulatory Approval James P. Oberhauser, Ph.D.
Medical Product Development: Commercial Success Extends Beyond Regulatory Approval James P. Oberhauser, Ph.D. Associate Director, Device Development and Clinical Packaging Engineering Gilead Sciences,
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More informationPresente e futuro degli stents bio-riassorbibili: fact or finction? Francesco Bedogni IRCCS Policlinico San Donato
Presente e futuro degli stents bio-riassorbibili: fact or finction? Francesco Bedogni IRCCS Policlinico San Donato Igaki-Tamai stent at 10 years! C D E Gold markers * E * B D C A B * * A Onuma Y et al.
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the XIENCE Everolimus Eluting Stent Bernard Chevalier
More informationInterventional cardiology has made great strides in
STEPHEN G. ELLIS, MD Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic HARIS RIAZ, MD Resident, Department of Internal Medicine, Cleveland Clinic Bioresorbable stents:
More informationDISCOVER Ultimaster with Optical Frequency Domain Imaging
DISCOVER Ultimaster with Optical Frequency Domain Imaging David Hildick-Smith Sussex Cardiac Centre Brighton and Sussex University Hospitals United Kingdom Potential conflicts of interest Speaker's name:
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationFANTOM II trial: Clinical results from the Fantom Sirolimus-Eluting BRS. Norbert Frey, MD University of Kiel, Germany
FANTOM II trial: Clinical results from the Fantom Sirolimus-Eluting BRS Norbert Frey, MD University of Kiel, Germany Potential conflicts of interest Speaker's name: Dr. Norbert Frey I have the following
More informationASX Small to Mid Caps New York Conference. March 1, 2012
ASX Small to Mid Caps New York Conference March 1, 2012 Important Notice Not an Offer for Securities This presentation has been prepared by REVA Medical, Inc. (REVA or the Company) solely for its use at
More informationElement Clinical Program Perseus Late Breaking News and the Platinum Study Design
Element Clinical Program Perseus Late Breaking News and the Platinum Study Design Ian T. Meredith MBBS, BSc(Hons), Ph.D, FRACP, FACC, FCSANZ, FSCAI, FAHA, FAPSIC Professor and Director of Monash HEART
More informationSecond Generation Drug Eluting Stents: From Inhibition to Healing
Second Generation Drug Eluting Stents: From Inhibition to Healing Mitchell W. Krucoff MD, FACC Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationInsights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up
Insights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up Ron Waksman, MD FACC FSCAI FESC Professor of Medicine, Georgetown University Director, Cardiovascular Research
More informationBioabsorbable Scaffolds - the future, Jacques Koolen
Bioabsorbable Scaffolds - the future, a passing fad or somewhere in between? Jacques Koolen Amsterdam POBA Acute closure Restenosis 3 months 30-50% BMS DES First generation Subacute-late trombus very
More informationOrbusNeich at TCT Late Breaking, Presentations and Poster Sessions
OrbusNeich at TCT Late Breaking, Presentations and Poster Sessions Booth No: 3011 MONDAY, OCTOBER 30 Special Session: 15th Anniversary HBD (Harmonization By Doing): New Synergies in Japan-U.S. Research
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the Everolimus Eluting Stent Bernard Chevalier
More informationDavide Capodanno, MD, PhD Associate Professor, University of Catania, Italy
Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 1 Autumn in Lucca V Simposio - 28 Novembre 2014 4.30PM-4.45PM L incubo del paziente e le incognite del cardiologo: la restenosi intrastent resta
More informationLEADERS FREE ACS EN - Rev.01
C.K. Naber, P. Urban, P.J. Ong, M. Valdes-Chavarri, A. Abizaid, S.J. Pocock, F. Fabbiocchi, C. Dubois, S. Copt, S. Greene and M.C. Morice for the LEADERS FREE Investigators Presented by CK Naber EuroPCR
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationDUREE de la BITHERAPIE dans les ETUDES LEADERS. J BERLAND Clinique Saint Hilaire ROUEN
DUREE de la BITHERAPIE dans les ETUDES LEADERS J BERLAND Clinique Saint Hilaire ROUEN LEADERS all-comers Trial Design Stable and ACS Patients Undergoing PCI Assessor-blind 1:1 Randomisation N=1700 Patients
More informationCOMPLEX CASES: LEFT MAIN
COMPLEX CASES: LEFT MAIN Resolute Onyx DES Together are trademarks of Medtronic. * Third-party brands are trademarks of For distribution only in markets where the Resolute Onyx coronary stent has been
More informationMid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
More information